Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,419.13 156.57 0.96%
S&P 500 1,860.27 17.29 0.94%
NASDAQ 4,085.02 50.86 1.26%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Biotie Therapies Oyj : Amendment to the release on UCB license of worldwide rights to tozadenant in Parkinson's disease from



 Biotie Therapies Oyj : Amendment to the release on UCB license of worldwide
           rights to tozadenant in Parkinson's disease from Biotie

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 27 February 2013 at 9.00 a.m.

Amendment to the release on UCB license of worldwide rights to tozadenant in
Parkinson's disease from Biotie

With reference to the stock exchange release on 26 February 2013 at 7:00 p.m.
Biotie clarifies that the additional milestones under the revised agreement
and Biotie being responsible for conducting phase 3 development of tozadenant
are not likely to have significant impact on profitability of Biotie during
the duration of the clinical development. The amended release in its entirety
may be found below.

UCB to license worldwide rights to tozadenant in Parkinson's disease from
Biotie

  * Novel product in development for the treatment of people living with
    Parkinson's disease 

  * Biotie receives USD 20 million license fee payment 

  * Original agreement modified: Biotie to conduct phase 3 development 

Biotie and UCB announced today that UCB has licensed worldwide exclusive
rights to Biotie's tozadenant (SYN115), a selective inhibitor of the adenosine
2a receptor, currently in development for the treatment of Parkinson's
disease. As a result, Biotie will receive a one-time fee payment of USD 20
million from UCB. In addition, the parties have amended their original license
agreement, such that Biotie will now conduct phase 3 development of tozadenant
in return for additional payments from UCB relating to defined development,
regulatory and commercialization milestones.

"UCB is committed to improving the lives of people with Parkinson's disease
and currently provides Neupro® a transdermal dopamine agonist for the
symptomatic treatment of all stages of idiopathic Parkinson's disease," said
Professor Dr Iris Loew-Friedrich, Chief Medical Officer and Executive Vice
President UCB. "Biotie is a valuable partner and the decision to in-license
follows the positive top-line results of the phase 2b study. We were impressed
by the performance of Biotie and decided that they are the ideal party to
continue to spearhead the development of tozadenant. We look forward to
collaborating with Biotie in the on-going clinical development. With the
addition of the novel compound tozadenant to UCB's development portfolio we
should be able to further contribute to the advancement of the treatment and
care for people living with Parkinson's disease."

The phase 2b study was a double-blind, randomized, placebo-controlled study
evaluating the safety and efficacy of tozadenant as adjunctive therapy in
levodopa-treated Parkinson's patients with end of dose wearing off. Results
from the phase 2b study are expected to be presented at upcoming medical
conferences and in scientific publications. Patient enrollment in the phase 3
program is currently planned to commence by the first half of 2015.

The original agreement between UCB and Biotie was announced in 2010. Under the
terms of the original agreement UCB will make an immediate one-time payment of
USD 20 million to Biotie and Biotie will remain eligible to a potential
additional USD 340 million in future milestone payments. Under the revised
agreement, Biotie will be eligible for additional payments in the low triple
digit millions in total over the next six years based on the successful
completion of defined development, regulatory and commercialization
milestones. The final amounts of the additional payments are to be determined
between the parties upon completion of the study plans in the coming months.
The additional milestone payments are likely not to significantly impact
Biotie's profitability during the duration of the clinical development. UCB
and Biotie will collaborate on the on-going clinical development and UCB will
be responsible for the manufacture and commercialization of tozadenant.

"We are thrilled with the opportunity to continue the development of
tozadenant in partnership with UCB", said Timo Veromaa, President and Chief
Executive Officer of Biotie. "We are encouraged by the vote of confidence
provided to us by UCB to continue with us the development of tozadenant and
the very significant incremental financial resources that we will be given to
complete the clinical work."

Turku, 27 February 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8911, e-mail: virve.nurmi@biotie.com

www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media

About Parkinson's disease

Parkinson's disease is a chronic, degenerative neurological disease. It is
commonly associated with movement (motor) symptoms such as tremors
(uncontrollable shaking), rigidity (stiffness or muscle tensing) and
bradykinesia (slowness and loss of spontaneous movement), but also commonly
causes underlying symptoms such as mood and cognitive impairment, pain,
depression and fatigue.

About tozadenant (SYN115)

Tozadenant is an orally administered, selective inhibitor of the adenosine 2a
(A2a) receptor being developed initially for the treatment of Parkinson's
disease. A2a receptors are expressed in high concentration in the striatum of
the brain and are thought to play an important role in regulating motor
function. Tozadenant blocks the effect of endogenous adenosine at the A2a
receptors, resulting in the potentiation of the effect of dopamine and
inhibition of the effect of glutamate at the mGluR5 receptor.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company
focused on the discovery and development of innovative medicines and solutions
to transform the lives of people living with severe diseases of the immune
system or of the central nervous system. With more than 8 500 people in about
40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is
listed on Euronext Brussels (symbol: UCB).

About Biotie (www.biotie.com)

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's
disease, Alzheimer's disease and other cognitive disorders, alcohol and drug
dependence (addiction) and post-traumatic stress disorder), and inflammatory
and fibrotic liver disease. The company has a strong and balanced development
portfolio with several innovative small molecule and biological drug
candidates at different stages of clinical development. Biotie's products
address diseases with high unmet medical need and significant market
potential.

Biotie's most advanced product, Selincro(TM) (nalmefene), licensed to Lundbeck
A/S, has on 14 December 2012 received a positive opinion from the Committee
for Medicinal Products for Human Use (CHMP) of the European Medicines Agency
(EMA) recommending marketing authorization of Selincro(TM) for the reduction
of alcohol consumption in adult patients with alcohol dependence who have a
high level of alcohol consumption. In addition, Biotie has a strategic
collaboration with UCB Pharma S.A. covering tozadenant which has successfully
completed a Phase 2b study in 420 patients with advanced Parkinson's disease.
Biotie shares are listed on NASDAQ OMX Helsinki Ltd. Symbol: BTH1V

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Biotie Therapies Oyj via Thomson Reuters ONE
HUG#1681399
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement